FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3143309498> ?p ?o ?g. }

• W3143309498 endingPage "678" @default.
• W3143309498 startingPage "678" @default.
• W3143309498 abstract "Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men.To investigate the efficacy and safety of dapagliflozin compared with placebo in men and women with HFrEF enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).Prespecified subgroup analysis of a phase 3 randomized clinical trial conducted at 410 sites in 20 countries. Patients with New York Heart Association functional class II through IV with an ejection fraction of 40% or less and elevated N-terminal pro-B-type natriuretic peptide were eligible. Data were analyzed between June 2020 and January 2021.Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy.The primary outcome was the composite of an episode of worsening HF (HF hospitalization or urgent HF visit requiring intravenous therapy) or cardiovascular death.A total of 4744 patients were randomized in DAPA-HF, of whom 1109 were women (23.4%). Compared with placebo, dapagliflozin reduced the risk of worsening HF events or cardiovascular death to a similar extent in both men and women (hazard ratios, 0.73 [95% CI, 0.63-0.85] and 0.79 [95% CI, 0.59-1.06], respectively; P for interaction = .67). Consistent benefits were observed for the components of the primary outcome and all-cause mortality. Compared with placebo, dapagliflozin increased the proportion of patients with a meaningful improvement in symptoms (Kansas City Cardiomyopathy Questionnaire total symptom score of ≥5 points; men, 59% vs 50%; women, 57% vs 54%; P for interaction = .14) and decreased the proportion with worsening symptoms (Kansas City Cardiomyopathy Questionnaire total symptom score decrease of ≥5 points; men, 25% vs 34%; women, 27% vs 31%; P for interaction = .15), irrespective of sex. Results were consistent for the Kansas City Cardiomyopathy Questionnaire clinical summary score and overall summary score. Study drug discontinuation and serious adverse events were not more frequent in the dapagliflozin group than in the placebo group in either men or women.Dapagliflozin reduced the risk of worsening HF, cardiovascular death, and all-cause death and improved symptoms, physical function, and health-related quality of life similarly in men and women with heart failure and reduced ejection fraction. In addition, dapagliflozin was safe and well-tolerated irrespective of sex.ClinicalTrials.gov Identifier: NCT03036124." @default.
• W3143309498 created "2021-04-13" @default.
• W3143309498 creator A5007964446 @default.
• W3143309498 creator A5012551917 @default.
• W3143309498 creator A5018432247 @default.
• W3143309498 creator A5024144703 @default.
• W3143309498 creator A5030053531 @default.
• W3143309498 creator A5030057930 @default.
• W3143309498 creator A5030399648 @default.
• W3143309498 creator A5032789207 @default.
• W3143309498 creator A5033436516 @default.
• W3143309498 creator A5034537174 @default.
• W3143309498 creator A5035803645 @default.
• W3143309498 creator A5046320799 @default.
• W3143309498 creator A5048450888 @default.
• W3143309498 creator A5051957671 @default.
• W3143309498 creator A5052533254 @default.
• W3143309498 creator A5054830306 @default.
• W3143309498 creator A5055441634 @default.
• W3143309498 creator A5066275468 @default.
• W3143309498 creator A5070440821 @default.
• W3143309498 creator A5072906007 @default.
• W3143309498 creator A5073798303 @default.
• W3143309498 date "2021-06-01" @default.
• W3143309498 modified "2023-10-02" @default.
• W3143309498 title "Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction" @default.
• W3143309498 cites W1965518725 @default.
• W3143309498 cites W2009415943 @default.
• W3143309498 cites W2023582771 @default.
• W3143309498 cites W2029210118 @default.
• W3143309498 cites W204483368 @default.
• W3143309498 cites W2047553605 @default.
• W3143309498 cites W2104915788 @default.
• W3143309498 cites W2112925036 @default.
• W3143309498 cites W2113320564 @default.
• W3143309498 cites W2113698123 @default.
• W3143309498 cites W2130610592 @default.
• W3143309498 cites W2136642260 @default.
• W3143309498 cites W2139371889 @default.
• W3143309498 cites W2144869700 @default.
• W3143309498 cites W2146931653 @default.
• W3143309498 cites W2150184024 @default.
• W3143309498 cites W2323639081 @default.
• W3143309498 cites W2412800896 @default.
• W3143309498 cites W2498901811 @default.
• W3143309498 cites W2582603147 @default.
• W3143309498 cites W2592398938 @default.
• W3143309498 cites W2625462710 @default.
• W3143309498 cites W2653321410 @default.
• W3143309498 cites W2741979119 @default.
• W3143309498 cites W2752162750 @default.
• W3143309498 cites W2781483265 @default.
• W3143309498 cites W2790286202 @default.
• W3143309498 cites W2888524010 @default.
• W3143309498 cites W2909658418 @default.
• W3143309498 cites W2920899198 @default.
• W3143309498 cites W2974260792 @default.
• W3143309498 cites W2984683166 @default.
• W3143309498 cites W2987185485 @default.
• W3143309498 cites W3013207865 @default.
• W3143309498 cites W3022657362 @default.
• W3143309498 cites W3081830235 @default.
• W3143309498 cites W3083153332 @default.
• W3143309498 cites W3102766101 @default.
• W3143309498 cites W3106240111 @default.
• W3143309498 cites W3109313492 @default.
• W3143309498 cites W4236654631 @default.
• W3143309498 cites W4238145439 @default.
• W3143309498 cites W4245386327 @default.
• W3143309498 cites W4245609902 @default.
• W3143309498 cites W4252616791 @default.
• W3143309498 cites W4253298559 @default.
• W3143309498 cites W4256291730 @default.
• W3143309498 cites W4233207332 @default.
• W3143309498 doi "https://doi.org/10.1001/jamacardio.2021.0379" @default.
• W3143309498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8014207" @default.
• W3143309498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33787831" @default.
• W3143309498 hasPublicationYear "2021" @default.
• W3143309498 type Work @default.
• W3143309498 sameAs 3143309498 @default.
• W3143309498 citedByCount "17" @default.
• W3143309498 countsByYear W31433094982021 @default.
• W3143309498 countsByYear W31433094982022 @default.
• W3143309498 countsByYear W31433094982023 @default.
• W3143309498 crossrefType "journal-article" @default.
• W3143309498 hasAuthorship W3143309498A5007964446 @default.
• W3143309498 hasAuthorship W3143309498A5012551917 @default.
• W3143309498 hasAuthorship W3143309498A5018432247 @default.
• W3143309498 hasAuthorship W3143309498A5024144703 @default.
• W3143309498 hasAuthorship W3143309498A5030053531 @default.
• W3143309498 hasAuthorship W3143309498A5030057930 @default.
• W3143309498 hasAuthorship W3143309498A5030399648 @default.
• W3143309498 hasAuthorship W3143309498A5032789207 @default.
• W3143309498 hasAuthorship W3143309498A5033436516 @default.
• W3143309498 hasAuthorship W3143309498A5034537174 @default.
• W3143309498 hasAuthorship W3143309498A5035803645 @default.
• W3143309498 hasAuthorship W3143309498A5046320799 @default.
• W3143309498 hasAuthorship W3143309498A5048450888 @default.

• next